Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Artificial Intelligence Assisted Innovative Low-cost Skin Testing Model to Accelerate Person-centered TB Prevention Services in Tanzania, Mozambique and Uganda (TEST4TPT)

10 novembre 2026 mis à jour par: Christiaan Mulder, KNCV Tuberculosis Foundation

TEST4TPT: AI Assisted Innovative Low-cost Skin Testing Model to Accelerate Person-centered TB Prevention Services in Tanzania, Mozambique and Uganda

The Artificial Intelligence Assisted Innovative Low-cost Skin Testing Model to Accelerate Person-centered TB Prevention Services in Tanzania, Mozambique and Uganda (TEST4TPT) project will evaluate a person-centered approach to improve access to tuberculosis infection (TBI) testing and linkage to tuberculosis preventive treatment (TPT) in Mozambique, Tanzania, and Uganda. The project will generate evidence on the feasibility, acceptability, clinical utility, diagnostic and operational performance, and implementation of a novel point-of-care TBI testing approach, including home- or community-based testing and artificial intelligence (AI)-assisted reading. By bringing testing closer to people at increased risk of tuberculosis (TB), TEST4TPT aims to reduce barriers to care, support timely TPT initiation, and contribute to improved completion of preventive treatment.

The overall goal of TEST4TPT is to evaluate an integrated, home-based approach to TBI testing using SIILTIBCY (an authorized diagnostic skin test used to detect TBI), community health worker (CHW)-facilitated support, and AI-assisted result reading, with the aim of improving initiation and completion of TPT among close contacts of people newly diagnosed with pulmonary TB disease.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Description détaillée

TEST4TPT is a type 2 hybrid effectiveness-implementation study designed to evaluate the effectiveness and implementation of an integrated approach to tuberculosis infection (TBI) testing and tuberculosis preventive treatment (TPT) delivery in Mozambique, Tanzania, and Uganda. The study comprises four complementary sub-studies. Sub-study 1 evaluates the performance and usability of an artificial intelligence (AI)-assisted approach for interpretation of the SIILTIBCY skin test using the SmartPatch and TBConnect application. Sub-study 2 is a pragmatic cluster-randomised trial comparing different models of TBI testing and TPT delivery, including facility- and home-based approaches. Sub-study 3 is a mixed-methods implementation evaluation examining the implementation of these approaches, including their feasibility and acceptability. Sub-study 4 comprises economic and impact assessments to evaluate the costs and broader potential impact of the approaches evaluated in the study.

The technological approach evaluated in Sub-study 1 combines the SIILTIBCY skin test with the SmartPatch and AI-driven TBConnect application. The SmartPatch is an adhesive patch applied to the participant's forearm at the site of SIILTIBCY administration. The patch contains a unique QR code used to link the participant to their record within the TBConnect platform and includes a removable circular section defining the area where the skin test is administered and subsequently read. The SmartPatch remains in place between administration and interpretation of the test.

Sub-study 1 consists of two complementary components: validation of the AI-assisted SIILTIBCY reading approach and an assessment of the usability and user experience of the SmartPatch and TBConnect system. The validation component assesses the performance and agreement of AI-assisted SIILTIBCY interpretation compared with standard interpretation by a trained healthcare worker. The usability component examines use of the technology by healthcare workers and community health workers, as well as participants' experiences of wearing the SmartPatch. A total of 330 household contacts of people with TB, aged five years or older, will participate across Mozambique, Tanzania, and Uganda.

At the follow-up visit, images of the SIILTIBCY administration site are captured through the TBConnect application for AI-assisted interpretation. The AI-assisted approach estimates the size of the induration and provides a corresponding test classification. The SmartPatch therefore supports standardised identification and imaging of the test site, while TBConnect provides the platform through which the images and AI-assisted interpretation are managed.

For validation, the AI-assisted interpretation is compared with a standard SIILTIBCY reading conducted independently by a trained healthcare worker. Both readings are performed on the same skin test and are conducted independently and under blinded conditions. The comparison evaluates the ability of the AI-assisted approach to correctly classify SIILTIBCY results and its agreement with the healthcare-worker reference reading, including agreement in the measured size of induration. During this validation sub-study, participant management and clinical decisions are based on the standard healthcare-worker reading rather than the AI-assisted result.

Sub-study 1 also assesses whether the SmartPatch and TBConnect approach is practical and acceptable to its intended users. Healthcare workers and community health workers with experience using the system are asked about its usability and its integration into routine activities, while participants provide information about their experience of wearing the SmartPatch. These findings complement the validation results by assessing not only whether the AI-assisted approach performs adequately, but also whether it can be feasibly used within the intended implementation context. Findings from Sub-study 1 will inform whether the AI-assisted approach is incorporated into the home-based testing approach evaluated in Sub-study 2.

Sub-study 2 is the main effectiveness evaluation and consists of a pragmatic cluster-randomised trial. Participating health facilities are allocated to three service-delivery approaches: standard-of-care facility-based assessment; facility-based SIILTIBCY testing and reading; or home-based SIILTIBCY testing and reading delivered by community health workers, where permitted by national guidelines. The home-based arm may incorporate AI-assisted interpretation using SmartPatch and TBConnect if this approach demonstrates adequate performance in Sub-study 1. Health facilities are used as clusters to allow consistent implementation of each approach within facility workflows and minimise contamination between study arms.

Sub-study 3 evaluates the implementation of the TEST4TPT approaches using an adapted RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance) framework, complemented by constructs from the Implementation Outcomes Framework. The evaluation considers reach, effectiveness and clinical utility, adoption, implementation, maintenance, feasibility and acceptability. A convergent mixed-methods approach combines implementation data generated during the study with qualitative interviews involving contact persons, community health workers, healthcare workers and TB/National Tuberculosis Programmes (NTP) policymakers or programme managers. This component is intended to provide an understanding of how and why the different TBI testing and TPT delivery approaches work across different settings, alongside the effectiveness results generated in Sub-study 2.

Sub-study 4 comprises the economic and impact assessments of the TEST4TPT approaches. This component evaluates the economic implications of the different TBI testing and TPT delivery strategies and their potential impact, complementing the effectiveness and implementation findings from the other sub-studies.

Type d'étude

Interventionnel

Inscription (Estimé)

1804

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

5 ans et plus (Enfant, Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Reside within the catchment area of one of the participating health facilities.
  • Be a close contact, as defined by country guidelines, of a person newly diagnosed with pulmonary tuberculosis disease, irrespective of drug susceptibility.
  • Be aged ≥5 years.
  • Be able to provide written informed consent. For participants below the legal age of consent, written informed consent must be obtained from a parent or legal guardian, with participant assent obtained where required by national regulations.

Exclusion Criteria:

  • Known contraindication to SIILTIBCY according to the manufacturer's instructions for use.
  • People with confirmed TB disease
  • Already on TPT at time of recruitment
  • Previous participation in this sub-study.
  • Presence of skin conditions at the intended injection site that may interfere with SIILTIBCY administration or interpretation of the induration (e.g. extensive dermatitis, burns, scars, or other clinically significant dermatological conditions).
  • Known disease associated with immunosuppression.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Standard of Care

Close contacts of people newly diagnosed with pulmonary tuberculosis (TB) receive routine facility-based contact investigation and assessment for eligibility for tuberculosis preventive treatment (TPT), according to national guidelines. Tuberculosis infection (TBI) testing may or may not be included, depending on local availability and standard practice

Facility-based identification and assessment of close contacts of people with pulmonary tuberculosis (TB), with assessment for tuberculosis preventive treatment (TPT) eligibility according to national guidelines. Tuberculosis infection (TBI) testing may or may not be included depending on local availability and practice.

Expérimental: Facility-based SIILTIBCY testing

Close contacts of people newly diagnosed with pulmonary tuberculosis (TB) receive facility-based SIILTIBCY testing, (an authorized diagnostic skin test used to detect TBI). SIILTIBCY is administered and subsequently read at the health facility by healthcare workers. Eligible participants are offered tuberculosis preventive treatment (TPT) according to study procedures and prevailing national guidelines.

Close contacts receive SIILTIBCY testing at the health facility. SIILTIBCY is administered intradermally and the test result is read 48-72 hours after administration at the health facility.

Expérimental: Home-based SIILTIBCY testing

Close contacts of people newly diagnosed with pulmonary tuberculosis (TB) receive home-based SIILTIBCY testing and reading delivered by community health workers, where permitted by national guidelines. Artificial Intelligence (AI)-assisted reading using the SmartPatch and TBConnect app may be incorporated if the approach is shown to be sufficiently reliable in Sub-study 1.

Close contacts will receive home-based tuberculosis (TB) infection screening and SIILTIBCY testing delivered by trained community health workers (CHWs), where permitted by national guidelines. CHWs will return to the household 48-72 hours after SIILTIBCY administration to assess the test result. AI-assisted interpretation using the SmartPatch and TBConnect application may be used if supported by the findings of Sub-study 1 and approved for use in the trial. Participants requiring further clinical assessment will be referred or linked to the health facility, and eligible participants will be linked to tuberculosis preventive treatment according to national guidelines.

The SmartPatch and AI-driven TBConnect application are used to support AI-assisted interpretation of the SIILTIBCY skin test. The SmartPatch is applied to the participant's forearm and linked to the TBConnect platform through a unique QR code. Images of the SIILTIBCY administration site are captured using TBConnect for AI-assisted interpretation.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of eligible contacts initiating tuberculosis preventive treatment per index TB patient
Délai: From sub-study 2 initiation through study completion, approximately 15 months

Number of eligible close contacts who initiate tuberculosis preventive treatment (TPT) per enrolled index TB patient, compared across study arms. This outcome will be used to assess the effectiveness of integrating home-based SIILTIBCY testing and reading into contact investigation compared with standard of care.

From sub-study 2 initiation through study completion, approximately 15 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Number of contacts identified per TB index patient
Délai: From sub-study 2 initiation through study completion, approximately 15 months

Number of household or other close contacts identified per TB index patient. The number of contacts identified per index patient will be calculated at cluster level and compared across the three study arms.

From sub-study 2 initiation through study completion, approximately 15 months
Proportion of estimated contacts identified
Délai: From sub-study 2 initiation through study completion, approximately 15 months

Proportion of the estimated contacts of TB index patients who are identified through contact investigation. The proportion will be calculated for each cluster and compared across the three study arms.

From sub-study 2 initiation through study completion, approximately 15 months
Proportion of estimated contacts screened for tuberculosis infection
Délai: From sub-study 2 initiation through study completion, approximately 15 months

Proportion of estimated contacts who undergo tuberculosis infection (TBI) screening. For participants receiving SIILTIBCY, completion of the test requires interpretation within the protocol-defined 48-72-hour reading window after administration.

From sub-study 2 initiation through study completion, approximately 15 months
Proportion of estimated contacts initiating tuberculosis preventive treatment
Délai: From sub-study 2 initiation through study completion, approximately 15 months

Proportion of estimated contacts who initiate tuberculosis preventive treatment (TPT). TPT initiation is recorded using the treatment start date and will be compared across study arms.

From sub-study 2 initiation through study completion, approximately 15 months
Proportion of estimated contacts completing tuberculosis preventive treatment
Délai: Measured throughout the sub-study 2 implementation period (15 months) and until the last enrolled participant completes the 3-month tuberculosis preventive treatment course (approximately 18 months total)

Proportion of estimated contacts who complete tuberculosis preventive treatment (TPT). Treatment completion status and completion date will be recorded and the outcome compared across study arms.

Measured throughout the sub-study 2 implementation period (15 months) and until the last enrolled participant completes the 3-month tuberculosis preventive treatment course (approximately 18 months total)
Occurrence of adverse events
Délai: Measured throughout the sub-study 2 implementation period (15 months) and until the last enrolled participant completes the 3-month tuberculosis preventive treatment course (approximately 18 months total)

Proportion of participants experiencing one or more adverse events during TBI testing or TPT, including the type, severity and relatedness of adverse events to the intervention, where applicable.

Measured throughout the sub-study 2 implementation period (15 months) and until the last enrolled participant completes the 3-month tuberculosis preventive treatment course (approximately 18 months total)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Les enquêteurs

  • Chercheur principal: Edine Tiemersma, Msc Phd, KNCV Tuberculosis Foundation

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 avril 2027

Achèvement primaire (Estimé)

1 décembre 2028

Achèvement de l'étude (Estimé)

30 avril 2029

Dates d'inscription aux études

Première soumission

29 octobre 2026

Première soumission répondant aux critères de contrôle qualité

10 novembre 2026

Première publication (Réel)

13 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 101249120

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified individual participant data underlying study publications may be made available in accordance with the TEST4TPT Data Management Plan, applicable ethical and legal requirements, and relevant data-sharing agreements. Shared datasets will exclude direct and indirect personal identifiers to minimise the risk of participant re-identification.

Délai de partage IPD

IPD and supporting information will be made available following publication of the primary study findings. Study records will be retained for a minimum of five years after publication of the final study results, or longer where required by sponsor policies, institutional requirements, or applicable national ethics, data protection, or privacy regulations.

Critères d'accès au partage IPD

Fully de-identified datasets may be made openly available through a suitable trusted research data repository. Where participant-level datasets cannot be made openly accessible because of ethical or legal restrictions, qualified external researchers may request access by submitting a data access request describing the intended scientific use. Requests will be reviewed by the study Principal Investigators prior to approval. Access will be subject to participant consent, ethical approvals, institutional policies, sponsor requirements, and applicable data protection regulations.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • ANALYTIC_CODE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .